Clinical Report: Evaluating Oral Ketamine for Treatment-Resistant Depression

Overview

Walter et al. conducted two studies assessing oral ketamine's safety and efficacy in treatment-resistant depression (TRD). While oral ketamine showed a benign adverse effect profile, it did not demonstrate statistically significant efficacy compared to placebo at day 21 in the phase 2 trial.

Background

Treatment-resistant depression (TRD) poses significant challenges in clinical practice, as patients often do not respond to standard antidepressant therapies. The exploration of alternative treatments, such as ketamine, is crucial. Understanding the pharmacokinetics and therapeutic potential of oral ketamine could inform future treatment strategies.

Data Highlights

Key Findings

• Oral ketamine demonstrated a benign adverse effect profile with minimal dissociation.
• Maximum plasma concentration of oral ketamine was significantly lower than that of intranasal esketamine.
• Exposure to metabolites norketamine and hydroxynorketamine was 2.5 to 3.3 times higher with oral ketamine.
• The phase 2 trial showed early significant reduction of depressive symptoms at days 4 and 7, but not at day 21.
• Current evidence from controlled trials is insufficient to support the efficacy of oral ketamine in TRD.
• Patients in the study had similar characteristics to those in other TRD studies, but the improvement in MADRS scores was modest.

Clinical Implications

Clinicians should be cautious in prescribing oral ketamine for TRD due to the lack of robust evidence supporting its efficacy.

Conclusion

The findings from Walter et al. indicate that current clinical trial results do not support the widespread use of oral ketamine in treating TRD.

Related Resources & Content

1. Walter et al., Source, Year -- Evaluating Oral Ketamine for Treatment-Resistant Depression: Is It Premature?
2. Brain — Investigating the Cognitive Neuroscience Behind Ketamine's Effects on Major Depression
3. Drugs - Real World Outcomes — Persistent Depressive Symptoms in Bipolar Depression Resistant to Treatment After Brief Ketamine Therapy
4. BMC Psychiatry (Springer) — Real-world evaluation of change in depressive symptoms among patients with treatment-resistant depression treated with esketamine
5. Frontiers in Psychiatry — Rapid reduction of suicidal ideation with transient dissociative and “drunken gait” symptoms after intranasal esketamine, with music intervention: a case report
6. Investigating the Cognitive Neuroscience Behind Ketamine's Effects on Major Depression
7. Persistent Depressive Symptoms in Bipolar Depression Resistant to Treatment After Brief Ketamine Therapy
8. Real-world evaluation of change in depressive symptoms among patients with treatment-resistant depression treated with esketamine
9. FDA Label for Esketamine
10. Oral ketamine for the treatment of major depressive and bipolar disorder, a randomized controlled trial and meta-analysis - ScienceDirect
11. Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression | New England Journal of Medicine